896 abstracts found.



Results filter

Whither metabolomics

Year:

Session type:

Karen H Vousden1
1Cancer Research UK Beatson Institute, Glasgow, UK

Small molecules in the selection and validation of cancer drug targets

Year:

Session type:

Ian Collins1
1The Institute of Cancer Research, London, UK

Whither localised therapies

Year:

Session type:

Tim Maughan1
1Cancer Research UK and Medical Research Council Oxford Institute for Radiation Oncology, Oxford, UK

Investigating small cell lung cancer molecular status and heterogeneity utilising circulating tumour cells

Year:

Session type:

Louise Carter1, Dominic G Rothwell1, Yaoyong Li2, Deborah J Burt1, Jenny Antonello1, Matthew G Krebs1,3, Jakub Chudziak1, Lynsey Priest1, Crispin Miller2, Gillian Ellison5, Fiona Blackhall3,4, Caroline Dive1, Ged Brady1
1Clinical and Experimental Pharmacology, Cancer Research UK Manchester Institute, Manchester, UK,2RNA Biology Group/ Computational Biology, Cancer Research UK Manchester Institute, Manchester, UK,3Christie NHS Foundation Trust, Manchester, UK,4Institute of Cancer Sciences, University of Manchester, Manchester, UK,55AstraZeneca Pharmaceuticals, Cheshire, UK

Liquid biopsies: genotyping circulating tumour cells

Year:

Session type:

David Planchard1
1Gustave Roussy, Paris, France

Introduction: New methods for tumour functional imaging

Year:

Session type:

Kevin Brindle1
1University of Cambridge, Cambridge, UK

Using next generation sequencing to characterise in detail the biological mechanisms that underpin genomic instability in ETV6-RUNX1 ALL and identify recurrent drivers associated with leukemic transformation

Year:

Session type:

Elli Papaemmanuil1
1Wellcome Trust Sanger Institute, Cambridge, UK

Developing novel radiotracers for positron emission tomography: probing different cancer phenotypes and therapy response in living subjects

Year:

Session type:

Eric O Aboagye1
1Imperial College London, London, UK

Development of precision medicine trials for Philadelphia chromosome-like acute lymphoblastic leukaemia

Year:

Session type:

Stephen Hunger1,2
1University of Colorado School of Medicine, Aurora, USA,2Children's Hospital Colorado, Aurora, USA

Integration of cancer genome sequencing and dynamic functional imaging to assess the metabolic effects of metformin in breast cancer: a neoadjuvant window of opportunity clinical study

Year:

Session type:

Simon Lord1,2, Neel Patel3, Dan Liu3, John Fenwick3, Fergus Gleeson3, Syed Haider1,2, Francesca Buffa1, Adrian Harris1,2
1Department of Oncology, University of Oxford, Oxford, UK,2Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK,3Oxford Cancer Imaging Centre, University of Oxford, Oxford, UK

Introduction: Drug resistance modelling – patients, organoids and mice

Year:

Session type:

David Adams1
1Wellcome Trust Sanger Institute, Cambridge, UK

Tumour detection, treatment planning and response assessment using functional magnetic resonance

Year:

Session type:

Martin O Leach1
1The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, UK, London, UK

Olaparib penetrates glioblastoma at therapeutic levels: results of stage 1 of the OPARATIC trial; a phase I study of olaparib in combination with temozolomide in patients with relapsed glioblastoma

Year:

Session type:

Anthony Chalmers1, Alan Jackson2, Helen Swaisland3, William Stewart4, Sarah Halford5, Rhoda Molife6, Darren Hargrave7, Alex McCormick3
1University of Glasgow, Glasgow, UK,2University of Manchester, Manchester, UK,3AstraZeneca Ltd, Macclesfield, UK,4NHS Greater Glasgow & Clyde, Glasgow, UK,5Cancer Research UK Drug Development Office, London, UK,6Royal Marsden Hospital, London, UK,7Great Ormond Street Hospital, London, UK

Introduction: Toxicities of anti-cancer therapies

Year:

Session type:

Sam Ahmedzai1
1University of Sheffield, Sheffield, UK

Cancer cell models as a therapeutic biomarker discovery platform

Year:

Session type:

Mathew Garnett1
1Wellcome Trust Sanger Institute, Cambridge, UK

Mucositis and personalised cancer medicine: supportive care makes excellent cancer care possible

Year:

Session type:

Dorothy Keefe1,2
1University of Adelaide, Adelaide, South Australia, Australia,2SA Cancer Service, Adelaide, South Australia, Australia

Unravelling therapy resistance in mouse models of human breast cancer

Year:

Session type:

Jos Jonkers1
1Netherlands Cancer Institute, Amsterdam, The Netherlands

Radiogenomics Consortium meta-analysis of four genome wide association studies of late toxicity after radiotherapy for prostate cancer

Year:

Session type:

Catharine West1, Gill Barnett2, Sarah Kerns3, Laura Fachal4, Neil Burnet2, Alison Dunning5, Antonio Gómez-Caamaño6, Harry Ostrer7, Paul Pharoah5, Barry Rosenstein3, Ana Vega4, Matt Parliament8
1University of Manchester, Manchester, UK,2Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK,3Icahn School of Medicine at Mount Sinai, New York, USA,4Fundación Pública Galega de Medicina Xenómica, Santiago de Compostela, Spain,5University of Cambridge, Cambridge, UK,6Complexo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain,7Albert Einstein College of Medicine, New York, USA,8Cross Cancer Institute, Alberta, Canada

Introduction: Human papilloma virus (HPV)-positive head and neck cancer

Year:

Session type:

Kevin Harrington1
1The Institute of Cancer Research, London, UK

A new era in understanding and managing chronic gastrointestinal (GI) consequences of cancer treatment

Year:

Session type:

Jervoise Andreyev1
1The Royal Marsden NHS Foundation Trust, London, UK

Human papillomavirus: the biology of carcinogenesis

Year:

Session type:

Ned Powell1
1Cardiff University, Cardiff, UK

Supportive care in cancer patients: a unifying concept

Year:

Session type:

Jean A Klastersky1
1Institut Jules Bordet - ULB, Brussels, Belgium

Clinical Trials Of MVA-EBNA1/LMP2, A Therapeutic Cancer Vaccine Designed To Treat Epstein-Barr Virus (EBV) Positive NasopharyngealCarcinoma (NPC)

Year:

Session type:

Neil Steven1,6, Kevin Harrington2, Lip Lee3, Edwin Hui9, Hui Jia1, David Price4, Kristin Ladell4, James Turner1, Manjit Tanday1, Claudia Roberts6,1, Ceri Edwards5, Lesley McGuigan5, Andrew Hartley6, Stephen Wilson7, Benjamin Johnson8, Anthony Chan9, Alan Rickinson1, Graham Taylor1
1School of Cancer Sciences, The University of Birmingham, Birmingham, England, UK,2Department of Cancer Biology, Institute of Cancer Research, London, England, UK,3Department of Clinical Oncology, The The Christie NHS Foundation Trust, Manchester, England, UK,4Institute of Infection and Immunity, Cardiff University School of Medicine, Cardiff, Wales, UK,5Drug Development Office, Cancer Research UK, London, England, UK,6University Hospital Birmingham NHS Foundation Trust, Birmingham, England, UK,7Health Protection Agency, West Midlands Public Health Laboratory, Birmingham, England, UK,8Section of Virology, Imperial College, London, England, UK,9The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China

Introduction: What makes a target attractive for cancer drug discovery

Year:

Session type:

Donald Ogilvie1
1ancer Research UK Manchester Institute, Manchester, UK

What differences should there be in the way we treat HPV +ve and HPV -ve squamous cell cancer of the head and neck?

Year:

Session type:

Kevin Harrington1
1The Institute of Cancer Research, London, UK

Identifying and prosecuting the right targets in oncology

Year:

Session type:

Graeme Smith1
1AstraZeneca, Alderly Park, UK

The immune response in HPV-positive oropharyngeal cancer

Year:

Session type:

Gareth Thomas1
1University of Southampton, Southampton, UK

Introduction:Lung cancer and mesothelioma

Year:

Session type:

Marianne Nicolson1
1Royal Aberdeen Infirmary, Aberdeen, UK

Genomics of lung cancer

Year:

Session type:

Ramaswamy Govindan1
1Washington University School of Medicine, St Louis, USA

PET imaging of DNA damage using 89Zr-labelled anti-γH2AX-TAT immunoconjugates

Year:

Session type:

James Knight1, Caitriona Topping1, Veerle Kersemans1, Nadia Falzone2, Nicola Sibson1, Bart Cornelissen1
1University of Oxford, Oxford, UK,2Institute for Cancer Research, Sutton, Surrey, UK

Introduction: Molecular profiling of childhood cancers

Year:

Session type:

Christine Harrison1
1Northern Institute for Cancer Research, Newcastle, UK,2Royal Victoria Infirmary, Newcastle, UK

APOBEC3B mutagenesis in cancer: basic mechanisms and clinical implications

Year:

Session type:

Reuben Harris1
1University of Minnesota, Minneapolis, UK

Exploiting biological heterogeneity to improve outcomes in childhood medulloblastoma

Year:

Session type:

Steven Clifford1
1Northern Institute for Cancer Research, Newcastle University, Newcastle, UK

DNA repair defects, PARP inhibitors and metastatic prostate cancer

Year:

Session type:

Johann de Bono1
1The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK

Routine molecular subgrouping of medulloblastoma: Bridging the divide between research and the clinic using low-cost DNA methylomics

Year:

Session type:

Edward Schwalbe1,2, Debbie Hicks1, Henning Gohlke3, Gholamreza Rafiee1, Amir Enshaei1, Sandeep Potluri1, Jessica Matthiesen1, Michael Mather1, Ria Chaston4, Steven Crosier1, Amanda Smith1, Daniel Williamson1, Simon Bailey1, Steven Clifford1
1Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK,2Northumbria University, Newcastle upon Tyne, UK,3Sequenom, Hamburg, Germany,4NewGene, Newcastle upon Tyne, UK

A patient viewpoint – integrate oncology and palliative care

Year:

Session type:

Roger Wilson1,2
1NCRI Consumer Liaison Group, London, UK,2Sarcoma UK, London, UK

A ‘battle’ or a ‘journey’? A large-scale study of metaphors for cancer

Year:

Session type:

Elena Semino1, Zsofia Demjen2, Jane Demmen1, Andrew Hardie1, Veronika Koller1, Sheila Payne1, Paul Rayson1
1Lancaster University, Lancaster, UK,2Open University, Milton Keynes, UK

Integrating palliative care into oncology – improving the palliative care of cancer patients in the care pathway

Year:

Session type:

Tiina Saarto1
1Helsinki University and Helsinki University Central Hospital, Helsinki, Finland

A phase II mixed-methods study on early integration of palliative care in advanced respiratory and gastrointestinal cancer patients

Year:

Session type:

Massimo Costantini1
1Hospital of Santa Maria Nuova, Florence, Italy

Introduction: Melanoma

Year:

Session type:

Pippa Corrie1
1Addenbrooke's Hospital, Cambridge, UK

In vivo RNAi screening for novel therapeutic cancer targets

Year:

Session type:

Daniel Peeper1
1Netherlands Cancer Institute, Amsterdam, The Netherlands

G12DNRAS and kinase-dead BRAF cooperate to drive naevogenesis and melanomagenesis

Year:

Session type:

Malin Pedersen1, Amaya Viros2, Martin Cook2, Richard Marais2
1The Institute of Cancer Research, London, UK,2The Cancer Research UK Manchester Institute, Manchester, UK

The aging microenviroment promotes metastasis and therapy resistance

Year:

Session type:

Ashani T Weeraratna1
1Melanoma Research Center, The Wistar Institute, Philadelphia, USA

A modern interpretation of the 5 Rs of radiobiology and their impact on clinical practice

Year:

Session type:

Kevin Harrington1
1The Institute of Cancer Research, London, UK

Tumour heterogeneity and co-operative behaviour in melanoma 

Year:

Session type:

Claudia Wellbrock1
1Manchester Cancer Research Centre, University of Manchester, Manchester, UK

Combining radiotherapy with DNA repair inhibitors in the lab and the clinic

Year:

Session type:

Anthony Chalmers1
1University of Glasgow, Glasgow, UK

Introduction: Molecular pathology – the genomic basis of cancer

Year:

Session type:

Manuel Salto-Tellez1
1Queen’s University Belfast, Belfast, UK

Genetic screens exploring tumour radiosensitivity 

Year:

Session type:

Geoff Higgins1
1Cancer Research UK and Medical Research Council Oxford Institute for Radiation Oncology, Oxford, UK

Epidermal growth factor receptor copy number gain (EGFR CNG) and response to gefitinib in oesophageal cancer (OC): Results of a biomarker analysis of a phase III  trial of gefitinib versus placebo (TRANS-COG).

Year:

Session type:

Russell Petty1,14, Asa Dahle-Smith1,14, Zofia Miedzybrodzka1,14, Susan Dutton2, Graeme Murray1,14, David Stevenson14, Doreen Massie14, Aileen Osbourne14, Caroline Clark14, Was Mansoor5, Joyce Thompson6, Mark Harrison7, Anirban Chatterjee8, Stephen Falk4, Sean Elyan9, Angel Garcia-Alonso10, David Fyfe12, Ian Chau11, Corran Roberts2, David Ferry13,2
1University of Aberdeen, Aberdeen, UK,2University of Oxford, Oxford, UK,3New Cross Hospital, Wolverhampton, UK,4University Hospitals Bristol NHS Foundation Trust, Bristol, UK,5Christie Hospital, Manchester, UK,6Birmingham Heartlands Hospital, Brimingham, UK,7Mount Vernon Cancer Centre, London, UK,8Royal Shrewsbury Hospital, Shrewsbury, UK,9Cheltenham General Hospital, Cheltenham, UK,10North Wales Cancer Centre, Rhyl, UK,11Royal Marsden Hospital, London, UK,12University Hospitals of Morrecombe Bay, Barrow in Furness, UK,13Lilly UK, Windlesham, UK,14NHS Grampian, Aberdeen, UK

Introduction: DNA repair in cancer biology and treatment

Year:

Session type:

Chris Lord1
1The Institute of Cancer Research, London, UK